Aldeyra Therapeu (ALDX) Stock Price, Quote & News

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally admini...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 761 4904

Fax: 339 674 6495

Website: www.aldeyra.com

Address:

131 Hartwell Avenue, Suite 320, Lexington, United States

EffingDeyra Mar. 21 at 12:16 PM

$ALDX Is this company moving? https://bostonagentmagazine.com/2026/01/26/131-hartwell-lexington/ Or have they already moved? Or is this just part of the building? Aldeyra's address is listed as 131 Hartwell Ave Suite 320

1 · Reply

TheREALElonsMusk Mar. 20 at 11:54 PM

$ALDX Another day ...any update from Abbvie? I cant find anything....

0 · Reply

GoldmanSlaps Mar. 20 at 8:44 PM

$ALDX homie dropped 100 grand 🤔

2 · Reply

ybk1234 Mar. 20 at 8:39 PM

$ALDX

1 · Reply

ybk1234 Mar. 20 at 8:38 PM

$ALDX https://ir.aldeyra.com/node/13071/html

0 · Reply

ThePorscheGuy Mar. 20 at 6:37 PM

$ALDX seems 1.10 was the bottom

0 · Reply

ThePorscheGuy Mar. 20 at 6:36 PM

$ALDX wow missed the dip

0 · Reply

HBerry Mar. 20 at 5:16 PM

$ALDX Interesting. Didn’t see this coming, but maybe I should have seen it with market value being under $75 after the drop. CEO still sucks. $15M due next week-still wonder what happens there. Not sure what he can with the FDA given that he said no more trials; reshuffle paperwork and bullsh## with the numbers and say I am resubmitting. They do have other items in the pipeline but IMO they need a new CEO to push ahead with anything.

2 · Reply

jerryemerydelacruz Mar. 20 at 4:54 PM

$ALDX Buy during an over exuberant drop is as profitable as selling at an over exuberant high.

0 · Reply

EvCe Mar. 20 at 4:19 PM

$ALDX let’s go 🚀🚀🚀

1 · Reply

What's Going On With Aldeyra Therapeutics Stock On Thursday?

Mar 17, 2026, 4:33 PM EDT - 4 days ago

Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 17, 2026, 8:36 AM EDT - 4 days ago

US FDA declines to approve Aldeyra's drug for eye disorder

Mar 17, 2026, 8:30 AM EDT - 4 days ago

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Feb 18, 2026, 7:01 AM EST - 4 weeks ago

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Dec 30, 2025, 6:26 PM EST - 2 months ago

Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst

Dec 16, 2025, 10:09 AM EST - 3 months ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript

Dec 15, 2025, 7:30 PM EST - 3 months ago

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Nov 13, 2025, 3:11 PM EST - 4 months ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript

Nov 13, 2025, 7:00 AM EST - 4 months ago

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Nov 11, 2025, 7:01 AM EST - 4 months ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:00 AM EST - 4 months ago

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Oct 28, 2025, 7:01 AM EDT - 5 months ago

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Oct 10, 2025, 4:32 AM EDT - 5 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALEC BDTX CHRS

Sep 3, 2025, 7:01 AM EDT - 7 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:01 AM EDT - 7 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aug 19, 2025, 7:01 AM EDT - 7 months ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 6, 2025, 7:01 AM EDT - 8 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 24, 2025, 7:00 AM EDT - 8 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Jul 17, 2025, 7:00 AM EDT - 8 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jul 2, 2025, 9:23 PM EDT - 9 months ago

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Jun 26, 2025, 7:00 AM EDT - 9 months ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

May 29, 2025, 7:01 AM EDT - 10 months ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 4:07 PM EDT - 11 months ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 11 months ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 4:42 PM EDT - 11 months ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

May 6, 2025, 3:48 PM EDT - 11 months ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 5, 2025, 6:34 PM EDT - 11 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 11 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 11 months ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 11 months ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 11 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 11 months ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 11 months ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

Apr 29, 2025, 9:49 AM EDT - 11 months ago

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 28, 2025, 9:00 PM EDT - 11 months ago

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

TTGT

Apr 28, 2025, 3:46 PM EDT - 11 months ago

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money

Apr 27, 2025, 8:20 AM EDT - 11 months ago

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

Apr 25, 2025, 3:22 PM EDT - 11 months ago

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law

EffingDeyra Mar. 21 at 12:16 PM

1 · Reply

TheREALElonsMusk Mar. 20 at 11:54 PM

$ALDX Another day ...any update from Abbvie? I cant find anything....

0 · Reply

GoldmanSlaps Mar. 20 at 8:44 PM

$ALDX homie dropped 100 grand 🤔

2 · Reply

ybk1234 Mar. 20 at 8:39 PM

$ALDX

1 · Reply

ybk1234 Mar. 20 at 8:38 PM

$ALDX https://ir.aldeyra.com/node/13071/html

0 · Reply

ThePorscheGuy Mar. 20 at 6:37 PM

$ALDX seems 1.10 was the bottom

0 · Reply

ThePorscheGuy Mar. 20 at 6:36 PM

$ALDX wow missed the dip

0 · Reply

HBerry Mar. 20 at 5:16 PM

2 · Reply

jerryemerydelacruz Mar. 20 at 4:54 PM

$ALDX Buy during an over exuberant drop is as profitable as selling at an over exuberant high.

0 · Reply

EvCe Mar. 20 at 4:19 PM

$ALDX let’s go 🚀🚀🚀

1 · Reply

Bigbas Mar. 20 at 4:00 PM

$ALDX almost back to my $2.12 average so looking like might get through a CRL unscathed, didn’t make money but didn’t lose hopefully

0 · Reply

StockBraker Mar. 20 at 3:59 PM

$ALDX Not much else to do on a down market day except run up the price of an oversold security - next stop $2.25. 😉💰

0 · Reply

StockBraker Mar. 20 at 3:51 PM

$ALDX At the risk of repeating myself.

0 · Reply

HappyStockholder Mar. 20 at 2:33 PM

$ALDX Are we witnessing the end of the dead cat bounce? This bounce back much weaker so far than the one after the last CRL.

2 · Reply

Costco_plays Mar. 20 at 1:53 PM

$ALDX put your money into $SWMR

0 · Reply

EvCe Mar. 20 at 1:39 PM

$ALDX slow and steady

0 · Reply

bernardbaruch Mar. 20 at 1:12 PM

$ALDX My thoughts are in random order: short squeeze; opex games; ATM was utilized heavily pre CRL; some combination of the above. I am having trouble reconciling how this company isn’t basically DOA

0 · Reply

Dragan7 Mar. 20 at 12:57 PM

$ALDX Looks like price will close around 2 today. Big boys are leading the game. All sellers of naked puts and puts buyers at 1.10 and around ( hoping to see price goes under 1 ) will lose money. Sure, Doggy and Steve will now say they have cashed in and they are already going long.

1 · Reply

CharlieeMungerTWITS Mar. 20 at 10:47 AM

$RYTM $ALDX $$$$$$$$

1 · Reply

Deep11 Mar. 20 at 9:03 AM

$ALDX holding 7400 shares with an average of $1.16.

0 · Reply

Tankman22 Mar. 20 at 8:55 AM

$ALDX LNKS .78, Low float/lots of cash play & IPO not long ago at 4$, regained nasdaq compliance recently & held over 1$ for awhile. They have a TON of cash while barely burning through it, we got over 1$ 3x yesterday also 🔥they also made a purchase of LPW company not long ago

0 · Reply

Smellmahass Mar. 20 at 8:21 AM

$ALDX Dang. Imagine buying at 1.10.

1 · Reply

Market Cap	85.46M
Revenue (ttm)	0.00
Net Income (ttm)	-33.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	1.39
Profit Margin	0.00%
Debt to Equity Ratio	0.34

Volume	10,645,101
Avg Vol	2,791,586
Day's Range	N/A - N/A
Shares Out	60.18M
Stochastic %K	16%
Beta	0.97
Analysts	Strong Sell
Price Target	$7.40